Iambic Therapeutics announced that Co-Founder and CEO Tom Miller will participate in a panel on AI in drug discovery at the Jefferies Global Healthcare Conference in London on November 18, 2026. Iambic uses an AI-driven platform to accelerate drug discovery and development, exemplified by their clinical candidate IAM1363. This event highlights Iambic's efforts to advance AI technology from concept to practical medical solutions, aiming to improve success rates in drug development. The conference is a major industry event featuring leaders in healthcare and biotech.
Iambic Therapeutics is set to participate in the Jefferies Global Healthcare Conference. For readers following the health sector, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: Out of 150 priced health-sector US stocks tradable on Pluang, 121 rose and 18 fell today. Notable movers include IONS at USD 31.20 with a 1-day change of -20.85%, IBRX at USD 7.49 down 13.26%, and ABEO at USD 3.65 down 12.47%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
